• Aptevo Therapeutics Inc APVO.OQ reported a quarterly adjusted loss of $33.48​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of $-6,393.60. The lone analyst forecast for the quarter was for a loss of $37.62 per share.

• Reported revenue was zero​; analysts expected zero.

• Aptevo Therapeutics Inc's reported EPS for the quarter was a loss of 1 cent​.

• The company reported a quarterly loss of $9.03 million.

• Aptevo Therapeutics Inc shares had fallen by 53.1% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 78.5% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Aptevo Therapeutics Inc is $21.00, about 78.5% above its last closing price of $4.51

This summary was machine generated from LSEG data March 26 at 09:57 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)